4//SEC Filing
Hurvitz Eli 4
Accession 0001209191-09-052681
CIK 0001006281other
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 4:30 PM ET
Size
15.3 KB
Accession
0001209191-09-052681
Insider Transaction Report
Form 4
Hurvitz Eli
Director
Transactions
- Sale
Common Stock
2009-11-12$10.76/sh−250,000$2,690,000→ 1,514,480 total(indirect: By Partnership) - Tax Payment
Common Stock
2009-11-12$11.33/sh−299$3,388→ 4,898,683 total(indirect: By Partnership) - Exercise/Conversion
Stock Options (Right to Buy)
2009-11-12−3,384,502→ 0 total(indirect: By Partnership)Exercise: $0.00Exp: 2010-03-16→ Common Stock (3,384,502 underlying) - Exercise/Conversion
Common Stock
2009-11-12$0.00/sh+3,384,502$3,385→ 4,898,982 total(indirect: By Partnership) - Other
Common Stock
2009-11-12−4,443,443→ 455,240 total - Sale
Common Stock
2009-11-12$10.00/sh−1,121,967$11,219,670→ 1,764,480 total(indirect: By Partnership)
Footnotes (8)
- [F1]Represents the sale by Pontifax (Cayman) L.P. and Pontifax (Israel) L.P. to cover the estimated applicable withholding tax for the transfer, described in this Form 4, of the common stock of Protalix BioTherapeutics, Inc. (the "Company") to their respective partners.
- [F2]Represents shares of common stock issued by the Company to Pontifax (Cayman) L.P. and Pontifax (Israel) L.P. upon the cashless exercise of options to purchase a total of 3,384,502 shares of common stock. Mr. Hurvitz disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- [F3]Represents shares of common stock withheld by the Company in connection with the exercise of the options by Pontifax (Cayman) L.P. and Pontifax (Israel) L.P.
- [F4]After exercising the options described in this Form 4, Pontifax (Cayman) L.P. and Pontifax (Israel) L.P. distributed all of their interests in the Company to their respective partners on a pro rata basis based on the percentage interest of each partner in the applicable partnership.
- [F5]The shares were transferred to the partners of each of Pontifax (Cayman) L.P. and Pontifax (Israel) L.P. on a pro rata basis based upon their percentage interests in the transferring partnership. No consideration was paid in connection with the transfer.
- [F6]Represents shares issued to the reporting person, Mr. Eli Hurvitz, a limited and general partner of Pontifax (Israel) L.P. and Pontifax (Cayman) L.P., in connection with the transfer. Such shares were retained by Mr. Hurvitz.
- [F7]All of the options vested prior to the date of the transaction.
- [F8]Represents all of the options issued to Pontifax (Cayman) L.P. and Pontifax (Israel) L.P. on December 31, 2006.
Documents
Issuer
Protalix BioTherapeutics, Inc.
CIK 0001006281
Entity typeother
Related Parties
1- filerCIK 0001385120
Filing Metadata
- Form type
- 4
- Filed
- Nov 12, 7:00 PM ET
- Accepted
- Nov 13, 4:30 PM ET
- Size
- 15.3 KB